|1.||Zhang, Li: 13 articles (09/2015 - 01/2011)|
|2.||Zhang, Shucai: 9 articles (12/2015 - 05/2013)|
|3.||Tan, Fenlai: 9 articles (09/2015 - 08/2011)|
|4.||Zhang, Yiping: 8 articles (10/2015 - 03/2013)|
|5.||Jiang, Ji: 8 articles (09/2015 - 07/2011)|
|6.||Sun, Yan: 7 articles (10/2015 - 09/2013)|
|7.||Hu, Pei: 7 articles (09/2015 - 07/2011)|
|8.||Zhao, Qiong: 6 articles (10/2015 - 08/2011)|
|9.||Shi, Yuankai: 6 articles (10/2015 - 09/2013)|
|10.||Zhou, Caicun: 5 articles (10/2015 - 09/2013)|
|1.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/01/2013 - "Icotinib could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer."
01/01/2014 - "This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-cell lung cancer (NSCLC). "
03/01/2013 - "[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified]."
09/01/2015 - "The current study was conducted to explore the relationship between icotinib hydrochloride exposure and therapeutic effects in Chinese patients with advanced non-small cell lung cancer (NSCLC) who were treated with icotinib hydrochloride. "
11/01/2014 - "A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)."
06/01/2012 - "Our results suggest the possibility of icotinib as a new therapeutic agent of EGFR-mutated cancer cells, which has the potential to be used in the first-line treatment of EGFR-mutated NSCLC."
08/01/2014 - "However, the exact molecular mechanism of icotinib's anti-tumor effect remains unknown. "
04/01/2014 - "Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects."
05/01/2013 - "Surprisingly we found that the tumor responded to icotinib again. "
05/01/2013 - "The tumor relapsed after a partial response and the patient was retreated with icotinib after temporary cessation. "
|3.||Neoplasm Metastasis (Metastasis)
09/01/2015 - "Univariate analysis showed that the ECOG PS score, parenchymal brain metastasis, and previous icotinib administration were significantly associated with patient survival. "
09/01/2015 - "A phase II study was conducted to evaluate the efficacy and safety of icotinib in combination with whole-brain radiotherapy (WBRT) in Chinese NSCLC patients with brain metastases (BMs); the cerebrospinal fluid (CSF)/plasma concentrations of icotinib were also investigated. "
01/01/2015 - "The icotinib treatment continued for four to eight months, or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity. "
11/01/2014 - "Among those with EGFR-sensitive mutation, the cumulative risk of brain metastasis was lower in the icotinib group than in the chemotherapy group. "
09/01/2014 - "Effective treatment with icotinib in primary adenoid cystic carcinoma of the lung with liver metastasis."
|4.||Lung Neoplasms (Lung Cancer)
12/20/2015 - "Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer. "
04/01/2014 - "Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer. "
04/01/2014 - "Icotinib (BPI-2009H, Conmana) is a novel oral quinazoline compound that has proven survival benefit in Chinese patients with lung cancer, for which several therapies are currently available often with unsatisfactory results. "
04/01/2014 - "Icotinib: activity and clinical application in Chinese patients with lung cancer."
01/01/2013 - "Icotinib significantly inhibited proliferation of the EGFR-mutated lung cancer HCC827 cells. "
08/01/2012 - "The efficacy of icotinib hydrochloride were related to the ECOG performance status, smoking history, EGFR mutation and rash significantly (P < 0.05). "
09/01/2013 - "The most common adverse events were rash (81 [41%] of 200 patients in the icotinib group vs 98 [49%] of 199 patients in the gefitinib group) and diarrhoea (43 [22%] vs 58 [29%]). "
09/01/2014 - "The common adverse reactions of Icotinib included rash, diarrhea, itching skin with occurrence rates of 24.6 % (17/69), 13.0 % (9/69), and 11.6 % (8/69), respectively. "
01/01/2014 - "However, afatinib and erlotinib showed significant severer rash and diarrhea compared with gefitinib and icotinib. "
|1.||Epidermal Growth Factor Receptor (EGF Receptor)
|3.||Adenocarcinoma of lung
|4.||Messenger RNA (mRNA)
|5.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|9.||erlotinib (CP 358,774)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)